The Phase 3 TRIUMPH-4 trial recorded 39.4% of participants achieving 30% or more weight loss at the 12mg dose over 68 weeks
Activation of GLP-1 receptor enhances neuronal base excision repair via PI3K-AKT-induced expression of apurinic/apyrimidinic endonuclease 1
Weissferdt A, Pataer A, Vaporciyan AA, Correa AM, Sepesi B, Moran CA, Wistuba II, Roth JA, Shewale JB, Heymach JV, Kalhor N, Cascone T, Hofstetter WL, Lee JJ, Swisher SG
and (b) an endophenotype class of Long COVID patients (31.7%) who show simultaneously severe abnormalities in SpO2 and PBT during acute COVID-19, and an increased OSTOX/ANTIOX ratio, CRP and increased total HAMD, HAMA and FF total and subdomain scores during Long COVID